Rigorous Blood Pressure Control May Be Beneficial for Patients with ADPKD

One of two HALT-PKD Clinical Trials Network studies demonstrated that rigorous blood pressure control conferred benefits over standard control related to a reduced rate of increase in total kidney volume and greater declines in measures of heart and kidney problems for patients with autosomal dominant polycystic kidney disease (ADPKD). However, the other study showed that dual blockade is not superior to an angiotensin-converting enzyme (ACE) inhibitor alone. Results indicate that ACE inhibitors alone or in combination with angiotensin receptor blockers are safe and achieve excellent blood pressure control in most patients with ADPKD. The studies were presented at ASN Kidney Week 2014 and published in NEJM.

Category:
Subcategory:
Body:

One of two HALT-PKD Clinical Trials Network studies demonstrated that rigorous blood pressure control conferred benefits over standard control related to a reduced rate of increase in total kidney volume and greater declines in measures of heart and kidney problems for patients with autosomal dominant polycystic kidney disease (ADPKD). However, the other study showed that dual blockade is not superior to an angiotensin-converting enzyme (ACE) inhibitor alone. Results indicate that ACE inhibitors alone or in combination with angiotensin receptor blockers are safe and achieve excellent blood pressure control in most patients with ADPKD. The studies were presented at ASN Kidney Week 2014 and published in NEJM.